These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28008744)

  • 21. FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis.
    Jiang T; Gao G; Fan G; Li M; Zhou C
    Lung Cancer; 2015 Jan; 87(1):1-7. PubMed ID: 25433983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
    Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
    Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma.
    Craddock KJ; Ludkovski O; Sykes J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2013 Nov; 8(11):1371-7. PubMed ID: 24077455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.
    Tran TN; Selinger CI; Kohonen-Corish MRJ; McCaughan BC; Kennedy CW; O'Toole SA; Cooper WA
    Lung Cancer; 2013 Sep; 81(3):462-467. PubMed ID: 23806793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
    Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
    Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Fibroblast Growth Factor Receptor 1 Gene Amplification and Human Papillomavirus Prevalence in Tonsillar Squamous Cell Carcinoma With Clinicopathologic Analysis.
    Park S; Lee M; Cho KJ; Kim SB; Roh JL; Choi SH; Nam SY; Kim SY; Song JS
    J Histochem Cytochem; 2018 Jul; 66(7):511-522. PubMed ID: 29553868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
    Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Jung DH; Shin SK; Lee SK; Lee YC; Kim HR; Moon YW; Kim JH; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
    Oncotarget; 2015 Feb; 6(4):2562-72. PubMed ID: 25537505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
    Sheng J; Fang W; Yu J; Chen N; Zhan J; Ma Y; Yang Y; Huang Y; Zhao H; Zhang L
    Sci Rep; 2016 Jan; 6():20090. PubMed ID: 26822379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome.
    Young RJ; Lim AM; Angel C; Collins M; Deb S; Corry J; Wiesenfeld D; Kleid S; Sigston E; Lyons B; Russell PA; Wright G; McArthur GA; Fox SB; Rischin D; Solomon B
    Oral Oncol; 2013 Jun; 49(6):576-81. PubMed ID: 23434054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
    J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
    Cihoric N; Savic S; Schneider S; Ackermann I; Bichsel-Naef M; Schmid RA; Lardinois D; Gugger M; Bubendorf L; Zlobec I; Tapia C
    Br J Cancer; 2014 Jun; 110(12):2914-22. PubMed ID: 24853178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH.
    Russell PA; Yu Y; Young RJ; Conron M; Wainer Z; Alam N; Solomon B; Wright GM
    Mod Pathol; 2014 Dec; 27(12):1621-31. PubMed ID: 24762544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
    Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
    Kim M; Kim H; Suh DH; Kim K; Kim H; Kim YB; No JH
    Anticancer Res; 2017 Sep; 37(9):5087-5094. PubMed ID: 28870938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.